Company news
Prime Medicine, Inc. (NASDAQ:PRME) news
Prime Medicine, Inc. news releases on 6ix. Latest, Oct 5, 2026: Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a…
Press releases & updates
Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease
October 5, 2026
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency
September 24, 2026
Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates
August 6, 2026
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease
July 23, 2026
Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics
July 8, 2026
Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
June 22, 2026
Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease
June 18, 2026
Prime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare Conference
June 3, 2026
Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates
May 7, 2026
Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer
April 16, 2026
Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates
March 3, 2026
Prime Medicine to Present at 44th Annual J.P. Morgan Healthcare Conference
January 7, 2026
Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease
December 7, 2025
Prime Medicine to Present at 8th Annual Evercore Healthcare Conference
November 25, 2025
Prime Medicine to Present at Jefferies Global Healthcare Conference
November 11, 2025
CORRECTION - Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates
November 7, 2025
Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates
November 7, 2025
Prime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer
November 3, 2025
Prime Medicine to Host Virtual KOL Event to Showcase Wilson’s Disease Strategy
October 30, 2025
Prime Medicine to Participate in Upcoming Investor Conferences
October 7, 2025
Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates
August 7, 2025
Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
August 1, 2025
Prime Medicine Announces Proposed Public Offering of Common Stock
July 30, 2025
Prime Medicine Announces Pricing of Public Offering
July 29, 2025
Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic Fibrosis
July 16, 2025
Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition
May 19, 2025
Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease
May 19, 2025
Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates
May 8, 2025
Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
March 18, 2025
Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates
February 28, 2025
Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference
February 24, 2025